Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 510

Cited In for PubMed (Select 8751444)

1.

CCR5 and HIV Infection, a View from Brussels.

Parmentier M.

Front Immunol. 2015 Jun 8;6:295. doi: 10.3389/fimmu.2015.00295. eCollection 2015. Review. No abstract available.

2.

Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.

Van Der Ryst E.

Front Immunol. 2015 Jun 5;6:277. doi: 10.3389/fimmu.2015.00277. eCollection 2015. Review. No abstract available.

3.

Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?

Lee WS, Parsons MS, Kent SJ, Lichtfuss M.

Front Immunol. 2015 May 27;6:265. doi: 10.3389/fimmu.2015.00265. eCollection 2015. Review. No abstract available.

4.

A Linear Epitope in the N-Terminal Domain of CCR5 and Its Interaction with Antibody.

Chain B, Arnold J, Akthar S, Brandt M, Davis D, Noursadeghi M, Lapp T, Ji C, Sankuratri S, Zhang Y, Govada L, Saridakis E, Chayen N.

PLoS One. 2015 Jun 1;10(6):e0128381. doi: 10.1371/journal.pone.0128381. eCollection 2015.

5.

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A, Delebecque F, Cornetta K, Rothe M, Baum C, Nicolson T, Koldej R, Zhang J, Keech N, Camba Colón J, Breton L, Bartlett J, An DS, Chen IS, Burke B, Symonds GP.

Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. doi: 10.1038/mtm.2013.11. eCollection 2014.

6.

Associations of common variants in the BST2 region with HIV-1 acquisition in African American and European American people who inject drugs.

Hancock DB, Gaddis NC, Levy JL, Bierut LJ, Kral AH, Johnson EO.

AIDS. 2015 Apr 24;29(7):767-77. doi: 10.1097/QAD.0000000000000604.

PMID:
25985399
7.

Novel genetic locus implicated for HIV-1 acquisition with putative regulatory links to HIV replication and infectivity: a genome-wide association study.

Johnson EO, Hancock DB, Gaddis NC, Levy JL, Page G, Novak SP, Glasheen C, Saccone NL, Rice JP, Moreau MP, Doheny KF, Romm JM, Brooks AI, Aouizerat BE, Bierut LJ, Kral AH.

PLoS One. 2015 Mar 18;10(3):e0118149. doi: 10.1371/journal.pone.0118149. eCollection 2015.

8.

p21(WAF1/CIP1) RNA expression in highly HIV-1 exposed, uninfected individuals.

Herbeck J, Ghorai S, Chen L, Rinaldo CR, Margolick JB, Detels R, Jacobson L, Wolinsky S, Mullins JI.

PLoS One. 2015 Mar 6;10(3):e0119218. doi: 10.1371/journal.pone.0119218. eCollection 2015.

9.

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.

Henrich TJ, McLaren PJ, Rao SS, Lin NH, Hanhauser E, Giguel F, Gulick RM, Ribaudo H, de Bakker PI, Kuritzkes DR.

Open Forum Infect Dis. 2014 May 22;1(1):ofu018. doi: 10.1093/ofid/ofu018. eCollection 2014 Mar.

10.

RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice.

Shimizu S, Ringpis GE, Marsden MD, Cortado RV, Wilhalme HM, Elashoff D, Zack JA, Chen IS, An DS.

Mol Ther Nucleic Acids. 2015 Feb 17;4:e227. doi: 10.1038/mtna.2015.3.

11.

The CD4 C868T Polymorphism and Its Correlation with HIV-1 Infection in a Chinese Population.

Lu Y, Wu J, Qin X, Xie L, Ma L, Huang X, Zhao J, Liu Y, Chen X, Li S.

AIDS Res Hum Retroviruses. 2015 May;31(5):525-30. doi: 10.1089/AID.2014.0303. Epub 2015 Mar 6.

PMID:
25611551
12.

The great opportunity: Evolutionary applications to medicine and public health.

Nesse RM, Stearns SC.

Evol Appl. 2008 Feb;1(1):28-48. doi: 10.1111/j.1752-4571.2007.00006.x.

13.

The CCR5Δ32 polymorphism in Brazilian patients with sickle cell disease.

Lopes MP, Santos MN, Faber EW, Bezerra MA, Hatzlhofer BL, Albuquerque DM, Zaccariotto TR, Ribeiro DM, Araújo Ada S, Costa FF, Sonati Mde F.

Dis Markers. 2014;2014:678246. doi: 10.1155/2014/678246. Epub 2014 Nov 11.

14.

CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.

Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P.

PLoS One. 2014 Dec 26;9(12):e115987. doi: 10.1371/journal.pone.0115987. eCollection 2014.

15.

Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, Vrbanac V, Garrison BS, Stortchevoi A, Bryder D, Musunuru K, Brand H, Tager AM, Allen TM, Talkowski ME, Rossi DJ, Cowan CA.

Cell Stem Cell. 2014 Nov 6;15(5):643-52. doi: 10.1016/j.stem.2014.10.004. Epub 2014 Nov 6.

PMID:
25517468
16.

Site-specific host gene modification by zinc finger nucleases: pointing the way to drug free control of HIV-1?

Sasson SC, Kelleher AD.

Clin Transl Immunology. 2014 Jul 11;3(7):e19. doi: 10.1038/cti.2014.12. eCollection 2014 Jul. Review.

17.

TRIM5α restriction affects clinical outcome and disease progression in simian immunodeficiency virus-infected rhesus macaques.

Wu F, Ourmanov I, Riddick N, Matsuda K, Whitted S, Plishka RJ, Buckler-White A, Starost MF, Hirsch VM.

J Virol. 2015 Feb;89(4):2233-40. doi: 10.1128/JVI.02978-14. Epub 2014 Dec 3.

PMID:
25473059
18.

Host genetics of Epstein-Barr virus infection, latency and disease.

Houldcroft CJ, Kellam P.

Rev Med Virol. 2015 Mar;25(2):71-84. doi: 10.1002/rmv.1816. Epub 2014 Nov 27.

19.

Cellular reprogramming for understanding and treating human disease.

Kanherkar RR, Bhatia-Dey N, Makarev E, Csoka AB.

Front Cell Dev Biol. 2014 Nov 12;2:67. doi: 10.3389/fcell.2014.00067. eCollection 2014. Review.

20.

Determining the specificities of TALENs, Cas9, and other genome-editing enzymes.

Pattanayak V, Guilinger JP, Liu DR.

Methods Enzymol. 2014;546:47-78. doi: 10.1016/B978-0-12-801185-0.00003-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk